APRI (Aprinoia Therapeutics) DeferredTaxAndRevenue: $0.02 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics DeferredTaxAndRevenue?

Aprinoia Therapeutics APRI DeferredTaxAndRevenue is $0.02 Mil as of Dec. 2023.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Aprinoia Therapeutics's current deferred tax and revenue for the quarter that ended in Dec. 2023 was $0.02 Mil.

Aprinoia Therapeutics DeferredTaxAndRevenue Related Terms

Aprinoia Therapeutics DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics DeferredTaxAndRevenue Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
DeferredTaxAndRevenue
0.09 0.21 0.02

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
DeferredTaxAndRevenue 0.09 0.00 0.21 0.02 0.02
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.02 Mil mean?
Aprinoia Therapeutics (APRI) has a DeferredTaxAndRevenue of $0.02 Mil as of Dec. 2023. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Aprinoia Therapeutics.
Is Aprinoia Therapeutics' DeferredTaxAndRevenue too high?
Aprinoia Therapeutics' current DeferredTaxAndRevenue is $0.02 Mil.
How does Aprinoia Therapeutics' DeferredTaxAndRevenue compare to ?
Aprinoia Therapeutics' DeferredTaxAndRevenue of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Aprinoia Therapeutics. Aprinoia Therapeutics's current DeferredTaxAndRevenue is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current DeferredTaxAndRevenue of $0.02 Mil. The current DeferredTaxAndRevenue is $0.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current DeferredTaxAndRevenue is $0.02 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.